Cibus (NASDAQ:CBUS - Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.19), Zacks reports. The company had revenue of $1.21 million during the quarter, compared to analysts' expectations of $1.13 million. Cibus had a negative net margin of 10,724.78% and a negative return on equity of 28.17%.
Cibus Price Performance
NASDAQ CBUS traded up $0.15 during trading on Monday, reaching $2.20. The company's stock had a trading volume of 132,868 shares, compared to its average volume of 166,770. The firm has a fifty day moving average of $2.33 and a 200 day moving average of $3.31. Cibus has a one year low of $1.80 and a one year high of $23.18. The stock has a market capitalization of $58.20 million, a PE ratio of -0.10 and a beta of 2.04.
Institutional Inflows and Outflows
An institutional investor recently raised its position in Cibus stock. Bank of America Corp DE boosted its position in Cibus, Inc. (NASDAQ:CBUS - Free Report) by 113.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 35,536 shares of the company's stock after acquiring an additional 18,885 shares during the quarter. Bank of America Corp DE owned 0.13% of Cibus worth $99,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 33.81% of the company's stock.
Wall Street Analyst Weigh In
A number of research firms have weighed in on CBUS. Canaccord Genuity Group reduced their target price on Cibus from $20.00 to $18.00 and set a "buy" rating for the company in a report on Wednesday, January 22nd. HC Wainwright reaffirmed a "buy" rating and set a $25.00 price objective on shares of Cibus in a research note on Friday.
Check Out Our Latest Research Report on Cibus
About Cibus
(
Get Free Report)
Cibus, Inc, a agricultural biotechnology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases.
Featured Stories
Before you consider Cibus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cibus wasn't on the list.
While Cibus currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
